Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Non-nucleoside antiretroviral agents]

D Sereni1, C Lascoux, V Gomez

  • 1Service de Médecine interne, Hôpital Cochin, Paris.

Presse Medicale (Paris, France : 1983)
|March 2, 1996
PubMed
Summary

New antiviral drugs, including protease inhibitors and non-nucleoside reverse transcriptase inhibitors, are being developed for HIV. Combination therapies show synergistic effects, reducing resistance and improving outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ablative techniques in renal tumours for inoperable patients: Step forward in SBRT.

Actas urologicas espanolas·2025
Same author

Marine debris and associated organic pollutants in surface waters of Chiloé in the Northern Chilean Patagonia (42°-44°S).

Marine pollution bulletin·2023
Same author

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.

Cell death & disease·2022
Same author

Hypofractionated whole breast irradiation after IORT treatment is safe in patients receiving adjuvant chemotherapy.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2021
Same author

Hypofractionated whole breast irradiation after IORT treatment: evaluation of acute toxicity and cosmesis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same author

Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC).

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2020

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Context:

  • Human immunodeficiency virus (HIV) treatment landscape is evolving.
  • Development of novel antiviral agents beyond nucleoside reverse transcriptase inhibitors is ongoing.
  • Emergence of drug resistance necessitates exploration of new therapeutic strategies.

Purpose:

  • To review current and emerging antiviral agents for HIV treatment.
  • To discuss the efficacy and challenges of various drug classes, including protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
  • To highlight the potential of combination therapy and other novel approaches.

Summary:

  • Protease inhibitors (e.g., saquinavir, ritonavir, indinavir) target viral release.
  • Non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine) offer good tolerance but risk early resistance.
  • Investigational therapies include antisense oligonucleotides, ribozymes, and gene inhibitors.
  • Combination therapy with multiple antiviral agents demonstrates synergistic effects, delaying resistance.
  • Immunomodulation and immunotherapy are also under investigation for HIV treatment.

Impact:

  • Combination antiviral therapy can reduce or delay drug resistance in HIV patients.
  • Novel therapeutic strategies offer hope for more effective HIV management.
  • Ongoing research into diverse approaches like gene inhibition and immunotherapy broadens treatment options.

Related Experiment Videos